Cargando…
Cryptogenic organizing pneumonia—Results of treatment with clarithromycin versus corticosteroids—Observational study
BACKGROUND: Cryptogenic organizing pneumonia (COP) is a clinicopathological syndrome of unknown origin. Corticosteroids are the standard treatment, but clarithromycin (CAM) is also effective. The aim of this observational retrospective study was to compare the results of CAM versus prednisone (PRE)...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5612459/ https://www.ncbi.nlm.nih.gov/pubmed/28945804 http://dx.doi.org/10.1371/journal.pone.0184739 |
_version_ | 1783266090768400384 |
---|---|
author | Radzikowska, Elżbieta Wiatr, Elżbieta Langfort, Renata Bestry, Iwona Skoczylas, Agnieszka Szczepulska-Wójcik, Ewa Gawryluk, Dariusz Rudziński, Piotr Chorostowska-Wynimko, Joanna Roszkowski-Śliż, Kazimierz |
author_facet | Radzikowska, Elżbieta Wiatr, Elżbieta Langfort, Renata Bestry, Iwona Skoczylas, Agnieszka Szczepulska-Wójcik, Ewa Gawryluk, Dariusz Rudziński, Piotr Chorostowska-Wynimko, Joanna Roszkowski-Śliż, Kazimierz |
author_sort | Radzikowska, Elżbieta |
collection | PubMed |
description | BACKGROUND: Cryptogenic organizing pneumonia (COP) is a clinicopathological syndrome of unknown origin. Corticosteroids are the standard treatment, but clarithromycin (CAM) is also effective. The aim of this observational retrospective study was to compare the results of CAM versus prednisone (PRE) treatment in patients with biopsy-proven OP without respiratory insufficiency. MATERIAL AND METHODS: In a 15-year period, 40 patients were treated with CAM (500 mg twice daily orally for 3 months) and 22 with PRE (mean initial dose of 0.67 ± 0.24 mg/kg/d for a mean of 8.59 ± 3.05 months). RESULTS: The clinical presentation, laboratory, and radiological findings did not differ markedly between patients treated with CAM and PRE, with the exception of a higher frequency of sweats (55% vs. 23%; p < 0.015), ground glass opacities (95% vs. 50%; p <0.0001) and nodular lesions (45% vs. 18%; p = 0.036) in the CAM group. A complete response was achieved in 35(88%) patients treated with CAM and in all treated with PRE. Patients treated with PRE relapsed more frequently than those treated with CAM (54.5% vs. 10%; p < 0.0001). Corticosteroid-related adverse events were noticed in 8(6.5%) patients (with one death), but CAM caused only one (2.5%) allergic reaction. A FVC >80% identified patients who might be successfully treated with CAM with a sensitivity of 60% and a specificity of 88.57% (AUC 0.869; 95% CI 0.684–1; p = 0.008); the figures for the FEV1 were >70%, a sensitivity of 60%, and a specificity of 91.43% (AUC 0.809; 95%CI 0.609–1; p = 0.027). CONCLUSIONS: CAM can be used to treat COP patients in whom the pulmonary function parameters are within normal limits. Such therapy is shorter, better tolerated, and associated with fewer adverse events and relapses than is PRE. However, the therapy is ineffective in some patients. |
format | Online Article Text |
id | pubmed-5612459 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-56124592017-10-09 Cryptogenic organizing pneumonia—Results of treatment with clarithromycin versus corticosteroids—Observational study Radzikowska, Elżbieta Wiatr, Elżbieta Langfort, Renata Bestry, Iwona Skoczylas, Agnieszka Szczepulska-Wójcik, Ewa Gawryluk, Dariusz Rudziński, Piotr Chorostowska-Wynimko, Joanna Roszkowski-Śliż, Kazimierz PLoS One Research Article BACKGROUND: Cryptogenic organizing pneumonia (COP) is a clinicopathological syndrome of unknown origin. Corticosteroids are the standard treatment, but clarithromycin (CAM) is also effective. The aim of this observational retrospective study was to compare the results of CAM versus prednisone (PRE) treatment in patients with biopsy-proven OP without respiratory insufficiency. MATERIAL AND METHODS: In a 15-year period, 40 patients were treated with CAM (500 mg twice daily orally for 3 months) and 22 with PRE (mean initial dose of 0.67 ± 0.24 mg/kg/d for a mean of 8.59 ± 3.05 months). RESULTS: The clinical presentation, laboratory, and radiological findings did not differ markedly between patients treated with CAM and PRE, with the exception of a higher frequency of sweats (55% vs. 23%; p < 0.015), ground glass opacities (95% vs. 50%; p <0.0001) and nodular lesions (45% vs. 18%; p = 0.036) in the CAM group. A complete response was achieved in 35(88%) patients treated with CAM and in all treated with PRE. Patients treated with PRE relapsed more frequently than those treated with CAM (54.5% vs. 10%; p < 0.0001). Corticosteroid-related adverse events were noticed in 8(6.5%) patients (with one death), but CAM caused only one (2.5%) allergic reaction. A FVC >80% identified patients who might be successfully treated with CAM with a sensitivity of 60% and a specificity of 88.57% (AUC 0.869; 95% CI 0.684–1; p = 0.008); the figures for the FEV1 were >70%, a sensitivity of 60%, and a specificity of 91.43% (AUC 0.809; 95%CI 0.609–1; p = 0.027). CONCLUSIONS: CAM can be used to treat COP patients in whom the pulmonary function parameters are within normal limits. Such therapy is shorter, better tolerated, and associated with fewer adverse events and relapses than is PRE. However, the therapy is ineffective in some patients. Public Library of Science 2017-09-25 /pmc/articles/PMC5612459/ /pubmed/28945804 http://dx.doi.org/10.1371/journal.pone.0184739 Text en © 2017 Radzikowska et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Radzikowska, Elżbieta Wiatr, Elżbieta Langfort, Renata Bestry, Iwona Skoczylas, Agnieszka Szczepulska-Wójcik, Ewa Gawryluk, Dariusz Rudziński, Piotr Chorostowska-Wynimko, Joanna Roszkowski-Śliż, Kazimierz Cryptogenic organizing pneumonia—Results of treatment with clarithromycin versus corticosteroids—Observational study |
title | Cryptogenic organizing pneumonia—Results of treatment with clarithromycin versus corticosteroids—Observational study |
title_full | Cryptogenic organizing pneumonia—Results of treatment with clarithromycin versus corticosteroids—Observational study |
title_fullStr | Cryptogenic organizing pneumonia—Results of treatment with clarithromycin versus corticosteroids—Observational study |
title_full_unstemmed | Cryptogenic organizing pneumonia—Results of treatment with clarithromycin versus corticosteroids—Observational study |
title_short | Cryptogenic organizing pneumonia—Results of treatment with clarithromycin versus corticosteroids—Observational study |
title_sort | cryptogenic organizing pneumonia—results of treatment with clarithromycin versus corticosteroids—observational study |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5612459/ https://www.ncbi.nlm.nih.gov/pubmed/28945804 http://dx.doi.org/10.1371/journal.pone.0184739 |
work_keys_str_mv | AT radzikowskaelzbieta cryptogenicorganizingpneumoniaresultsoftreatmentwithclarithromycinversuscorticosteroidsobservationalstudy AT wiatrelzbieta cryptogenicorganizingpneumoniaresultsoftreatmentwithclarithromycinversuscorticosteroidsobservationalstudy AT langfortrenata cryptogenicorganizingpneumoniaresultsoftreatmentwithclarithromycinversuscorticosteroidsobservationalstudy AT bestryiwona cryptogenicorganizingpneumoniaresultsoftreatmentwithclarithromycinversuscorticosteroidsobservationalstudy AT skoczylasagnieszka cryptogenicorganizingpneumoniaresultsoftreatmentwithclarithromycinversuscorticosteroidsobservationalstudy AT szczepulskawojcikewa cryptogenicorganizingpneumoniaresultsoftreatmentwithclarithromycinversuscorticosteroidsobservationalstudy AT gawrylukdariusz cryptogenicorganizingpneumoniaresultsoftreatmentwithclarithromycinversuscorticosteroidsobservationalstudy AT rudzinskipiotr cryptogenicorganizingpneumoniaresultsoftreatmentwithclarithromycinversuscorticosteroidsobservationalstudy AT chorostowskawynimkojoanna cryptogenicorganizingpneumoniaresultsoftreatmentwithclarithromycinversuscorticosteroidsobservationalstudy AT roszkowskislizkazimierz cryptogenicorganizingpneumoniaresultsoftreatmentwithclarithromycinversuscorticosteroidsobservationalstudy |